The mechanism of and the association between interleukin‑27 and chemotherapeutic drug sensitivity in lung cancer

Jiang,Bingdong; Shi,Wenbo; Li,Peng; Wu,Yanli; Li,Yun; Bao,Chuanming

doi:10.3892/ol.2020.12275

The mechanism of and the association between interleukin‑27 and chemotherapeutic drug sensitivity in lung cancer

Authors:
- Bingdong Jiang
- Wenbo Shi
- Peng Li
- Yanli Wu
- Yun Li
- Chuanming Bao
View Affiliations

Affiliations: Department of Medical Oncology, Jingmen No. 1 People's Hospital, Jingmen, Hubei 448000, P.R. China, Department of Oncology, The Central Hospital of Enshi Autonomous Prefecture, Enshi, Hubei 445000, P.R. China, Department of Radiotherapy, Jingmen No. 1 People's Hospital, Jingmen, Hubei 448000, P.R. China, Department of Oncology, Guangshui No. 1 People's Hospital, Guangshui, Hubei 432700, P.R. China, Department of Cardiothoracic Surgery, Suizhou Central Hospital, Suizhou, Hubei 441300, P.R. China
Published online on: November 6, 2020 https://doi.org/10.3892/ol.2020.12275
Article Number: 14
Copyright: © Jiang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Interleukins (ILs) are involved in the occurrence and development of numerous types of cancer, and serve a critical role in the development of effective cancer therapeutics. The aim of the present study was to investigate the effect of IL‑27 on chemotherapy resistance in lung cancer cells, and analyze its potential molecular mechanism in lung cancer tissues. Western blot analysis and reverse transcription‑quantitative polymerase chain reaction were performed to examine the RNA and protein expression levels of IL‑27. A Cell Counting Kit‑8 assay was performed to evaluate the proliferation rates of the lung cancer line A549. Flow cytometry was subsequently applied to determine the rate of apoptosis in A549 cells. The data obtained revealed that the expression of IL‑27 with cisplatin, significantly suppressed the proliferation and apoptosis of A549 cells compared with that in the cisplatin treatment group alone. The expression of Akt and apoptosis factors such as Caspase‑3 and Bcl‑2/Bax also ascertained that upregulated IL‑27 inhibited the development of cancer and increased apoptosis in the A549 cells. Therefore, IL‑27 may represent a potential target for antitumor therapy, especially when considering the clinical challenges presented by the development of chemoresistance in tumors. These findings suggest that IL‑27 is a promising biomarker and represents a novel treatment strategy for patients with lung cancer.

View Figures

View References

1	Gu Y, Liu S, Zhang X, Chen G, Liang H, Yu M, Liao Z, Zhou Y, Zhang CY, Wang T, et al: Oncogenic miR-19a and miR-19b co-regulate tumor suppressor MTUS1 to promote cell proliferation and migration in lung cancer. Protein Cell. 8:455–466. 2017. View Article : Google Scholar : PubMed/NCBI
2	Deng L, Tang Y, Lin J, Lu XJ, Xue JX, Wang LS, Zhou L, Zou Y, Ying BW, Li GD and Lu Y: Detection of epidermal growth factor receptor gene mutation in non-small cell lung cancer by allele-specific oligonucleotide-PCR and bi-loop probe specific primer quantitative PCR. Zhonghua Bing Li Xue Za Zhi. 41:20–22. 2012.(In Chinese). PubMed/NCBI
3	Lo Russo G, Proto C and Garassino MC: Afatinib in the treatment of squamous non-small cell lung cancer: A new frontier or an old mistake? Transl Lung Cancer Res. 5:110–114. 2016.PubMed/NCBI
4	Kazandjian D, Suzman DL, Blumenthal G, Mushti S, He K, Libeg M, Keegan P and Pazdur R: FDA approval summary: Nivolumab for the treatment of metastatic non-small cell lung cancer with progression on or after platinum-based chemotherapy. Oncologist. 21:634–642. 2016. View Article : Google Scholar : PubMed/NCBI
5	Antonia S, Goldberg SB, Balmanoukian A, Chaft JE, Sanborn RE, Gupta A, Narwal R, Steele K, Gu Y, Karakunnel JJ and Rizvi NA: Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: A multicentre, phase 1b study. Lancet Oncol. 17:299–308. 2016. View Article : Google Scholar : PubMed/NCBI
6	Zhou YY, Hu ZG, Zeng FJ and Han J: Clinical profile of cyclooxygenase-2 inhibitors in treating non-small cell lung cancer: A meta-analysis of nine randomized clinical trials. PLoS One. 11:e0151932016.
7	Fenchel K, Sellmann L and Dempke WC: Overall survival in non-small cell lung cancer-what is clinically meaningful? Transl Lung Cancer Res. 5:115–119. 2016.PubMed/NCBI
8	Wang W, Zhang L, Wang Y, Ding Y, Chen T, Wang Y, Wang H, Li Y, Duan K, Chen S, et al: Involvement of miR-451 in resistance to paclitaxel by regulating YWHAZ in breast cancer. Cell Death Dis. 8:e30712017. View Article : Google Scholar : PubMed/NCBI
9	Wu D, Lu P, Mi X and Miao J: Downregulation of mir-503 contributes to the development of drug resistance in ovarian cancer by targeting pi3k p85. Arch Gynecol Obstet. 297:699–707. 2018. View Article : Google Scholar : PubMed/NCBI
10	Siddik ZH: Cisplatin: Mode of cytotoxic action and molecular basis of resistance. Oncogene. 22:7265–7279. 2003. View Article : Google Scholar : PubMed/NCBI
11	Dasari S and Tchounwou PB: Cisplatin in cancer therapy: Molecular mechanisms of action. Eur J Pharmacol. 740:364–378. 2014. View Article : Google Scholar : PubMed/NCBI
12	He L, Luo L, Zhu H, Yang H, Zhang Y, Wu H, Sun H, Jiang F, Kathera CS, Liu L, et al: FEN1 promotes tumor progression and confers cisplatin resistance in non-small-cell lung cancer. Mol Oncol. 11:640–654. 2017. View Article : Google Scholar : PubMed/NCBI
13	Zhang PF, Sheng LL, Wang G, Tian M, Zhu LY, Zhang R, Zhang J and Zhu JS: miR-363 promotes proliferation and chemo-resistance of human gastric cancer via targeting of FBW7 ubiquitin ligase expression. Oncotarget. 7:35284–35292. 2016. View Article : Google Scholar : PubMed/NCBI
14	Krevvata M, Shan X, Zhou C, Dos Santos C, Habineza Ndikuyeze G, Secreto A, Glover J, Trotman W, Brake-Silla G, Nunez-Cruz S, et al: Cytokines increase engraftment of human acute myeloid leukemia cells in immunocompromised mice but not engraftment of human myelodysplastic syndrome cells. Haematologica. 103:959–971. 2018. View Article : Google Scholar : PubMed/NCBI
15	Nasiri M, Karimi MH, Azarpira N and Saadat I: Gene expression profile of toll-like receptor/adaptor/interferon regulatory factor/cytokine axis during liver regeneration after partial ischemia-reperfusion injury. Exp Clin Transplant. 2018.(Epub ahead of prin). PubMed/NCBI
16	Jiang YX, Yang SW, Li PA, Luo X, Li ZY, Hao YX and Yu PW: The promotion of the transformation of quiescent gastric cancer stem cells by IL-17 and the underlying mechanisms. Oncogene. 36:1256–1264. 2016. View Article : Google Scholar : PubMed/NCBI
17	Mantovani A, Barajon I and Garlanda C: IL-1 and IL-1 regulatory pathways in cancer progression and therapy. Immunol Rev. 281:57–61. 2018. View Article : Google Scholar : PubMed/NCBI
18	Anuradha R, Munisankar S, Bhootra Y, Dolla C, Kumaran P, Nutman TB and Babu S: Modulation of CD4+ and CD8+ T Cell Function and Cytokine Responses in Strongyloides stercoralis Infection by Interleukin-27 (IL-27) and IL-37. Infect Immun. 85(pii): e00500–17. 2017.PubMed/NCBI
19	Xu L, Zhu LL, Ye LL, Meng LJ, Liu WQ and Wang J: Percentages of peripheral blood gammadelta t cells and regulatory t cells and expression of associated cytokines in infants with human cytomegalovirus infection. Zhongguo Dang Dai Er Ke Za Zhi. 20:204–208. 2018.(In Chinese). PubMed/NCBI
20	Wu X, Tao P, Zhou Q, Li J, Yu Z, Wang X, Li J, Li C, Yan M, Zhu Z, et al: IL-6 secreted by cancer-associated fibroblasts promotes epithelial-mesenchymal transition and metastasis of gastric cancer via JAK2/STAT3 signaling pathway. Oncotarget. 8:20741–20750. 2017. View Article : Google Scholar : PubMed/NCBI
21	Yu XX, Hu Z, Shen X, Dong LY, Zhou WZ and Hu WH: IL-33 promotes gastric cancer cell invasion and migration via ST2-ERK1/2 pathway. Dig Dis Sci. 60:1265–1272. 2015. View Article : Google Scholar : PubMed/NCBI
22	Kopinski P, Wandtke T, Wedrowska E and Chorostowska-Wynimko J: Interleukin 27 in bronchoalveolar lavage fluid in patients with non- small cell lung cancer. Authors' reply. Pol Arch Intern Med. 128:266–268. 2018. View Article : Google Scholar : PubMed/NCBI
23	Liu Q, Yu YX, Wang XJ and Wang Z and Wang Z: Diagnostic accuracy of interleukin-27 between tuberculous pleural effusion and malignant pleural effusion: A meta-analysis. Respiration. 95:469–477. 2018. View Article : Google Scholar : PubMed/NCBI
24	Patel MV, Shen Z, Rossoll RM and Wira CR: IL-27 expression and responsiveness in human uterine epithelial cells and fibroblasts in vitro and the role of estradiol. J Interferon Cytokine Res. 38:101–110. 2018. View Article : Google Scholar : PubMed/NCBI
25	Zhu J, Liu JQ, Shi M, Cheng X, Ding M, Zhang JC, Davis JP, Varikuti S, Satoskar AR, Lu L, et al: IL-27 gene therapy induces depletion of tregs and enhances the efficacy of cancer immunotherapy. JCI Insight. 3(pii): 987452018. View Article : Google Scholar : PubMed/NCBI
26	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
27	Di Carlo E, Sorrentino C, Zorzoli A, Di Meo S, Tupone MG, Ognio E, Mincione G and Airoldi I: The antitumor potential of Interleukin-27 in prostate cancer. Oncotarget. 5:10332–10341. 2014. View Article : Google Scholar : PubMed/NCBI
28	Liu L, Meng J, Zhang C, Duan Y, Zhao L, Wang S and Shan B: Effects on apoptosis and cell cycle arrest contribute to the antitumor responses of interleukin-27 mediated by retrovirus in human pancreatic carcinoma cells. Oncol Rep. 27:1497–1503. 2012.PubMed/NCBI
29	Zhou WJ, Chang KK, Wu K, Yang HL, Mei J, Xie F, Li DJ and Li MQ: Rapamycin synergizes with cisplatin in antiendometrial cancer activation by improving IL-27-stimulated cytotoxicity of NK cells. Neoplasia. 20:69–79. 2018. View Article : Google Scholar : PubMed/NCBI
30	Zhang Z, Zhou B, Zhang K, Song Y, Zhang L and Xi M: IL-27 suppresses SKOV3 cells proliferation by enhancing STAT3 and inhibiting the Akt signal pathway. Mol Immunol. 78:155–163. 2016. View Article : Google Scholar : PubMed/NCBI
31	Cao JY, Yin HS, Li HS, Yu XQ and Han X: Interleukin-27 augments the inhibitory effects of sorafenib on bladder cancer cells. Braz J Med Biol Res. 50:e62072017. View Article : Google Scholar : PubMed/NCBI
32	Liu Z, Liu JQ, Talebian F, Wu LC, Li S and Bai XF: IL-27 enhances the survival of tumor antigen-specific CD8+ T cells and programs them into IL-10-producing, memory precursor-like effector cells. Eur J Immunol. 43:468–479. 2013. View Article : Google Scholar : PubMed/NCBI